Pulmonary Function Test (PFT) at Dr. Essa Lab

Pulmonary Function Test (PFT) at Dr. Essa Lab

A Pulmonary Function Test (PFT) at Dr. Essa Lab is a comprehensive, non-invasive diagnostic evaluation designed to assess the functional capacity of the respiratory system. Rather than providing a simple anatomical image, a PFT measures how effectively the lungs expand, how much air they can hold, how rapidly air can be inhaled and exhaled, and how efficiently the lungs transfer oxygen into the bloodstream while removing carbon dioxide. At Dr. Essa Lab, one of Pakistan’s premier diagnostic networks based in Karachi, these tests are performed using state-of-the-art computerized spirometers and advanced plethysmography equipment. This ensures that patients receive highly accurate, reproducible, and clinically precise measurements of their respiratory health.

The clinical importance of a Pulmonary Function Test cannot be overstated. It serves as the gold standard for differentiating between obstructive lung diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and restrictive lung diseases, such as idiopathic pulmonary fibrosis or chest wall deformities. By evaluating key physiological parameters, a PFT provides pulmonologists, thoracic surgeons, and general physicians with the objective data required to establish an accurate diagnosis, monitor disease progression, evaluate the efficacy of therapeutic interventions, and assess pre-operative risk for major surgical procedures. The diagnostic value of this test lies in its ability to detect early-stage respiratory impairment before significant structural changes become visible on conventional chest X-rays or CT scans.

Clinical Procedure: What to Expect

Patient Preparation

To ensure the highest degree of accuracy and reproducibility during your Pulmonary Function Test (PFT) at Dr. Essa Lab, patients must strictly adhere to the following preparation guidelines:

• Avoid Smoking: Do not smoke tobacco or use e-cigarettes for at least 6 hours prior to the test, as nicotine and smoke inhalation cause acute airway irritation and bronchoconstriction.
• Withhold Bronchodilators: If instructed by your referring physician, withhold short-acting bronchodilator inhalers (e.g., salbutamol) for 4 to 6 hours, and long-acting bronchodilators (e.g., salmeterol, formoterol) for 12 to 24 hours before the test to establish an accurate baseline.
• Avoid Heavy Meals: Refrain from eating a heavy meal for at least 2 hours before the procedure. A full stomach can restrict the downward movement of the diaphragm, artificially reducing measured lung volumes.
• Wear Loose Clothing: Wear comfortable, loose-fitting clothing that does not restrict your chest or abdominal expansion during deep breathing maneuvers.
• Avoid Strenuous Exercise: Do not engage in vigorous physical activity or strenuous exercise for at least 2 hours prior to the test.
• Avoid Alcohol and Caffeine: Avoid consuming alcoholic beverages and caffeinated drinks (tea, coffee, energy drinks) on the day of the test, as they can affect heart rate and airway smooth muscle tone.

During the Procedure

The Pulmonary Function Test is a safe, non-invasive, and highly collaborative procedure that relies heavily on patient effort and cooperation. Upon arriving at the Dr. Essa Lab diagnostic facility, you will be guided to a dedicated pulmonary function testing suite. You will be seated comfortably in an upright position in a chair. The clinical technologist will place a soft, comfortable clip on your nose to ensure that you breathe exclusively through your mouth during the evaluation.

You will then be instructed to place a sterile, disposable mouthpiece connected to the spirometer into your mouth, forming a tight seal with your lips to prevent any air leaks. The technologist will coach you through various breathing patterns. For a standard spirometry test, you will be asked to take a deep, maximal inspiration, followed immediately by a rapid, extremely forceful, and complete exhalation into the mouthpiece, continuing until your lungs are completely empty. This maneuver is typically repeated at least three times to ensure consistency and clinical validity. If a bronchodilator reversibility test is ordered, you will administer a puff of a quick-acting inhaler, wait approximately 15 minutes, and repeat the breathing maneuvers to assess for airway responsiveness. The entire procedure generally takes between 30 to 45 minutes, does not involve any radiation or injections, and is entirely safe under the supervision of our trained clinical staff.

When is a Pulmonary Function Test (PFT) Performed?

Diagnosis of Chronic Obstructive Pulmonary Disease (COPD)

Physicians frequently request a Pulmonary Function Test at Dr. Essa Lab to diagnose and grade the severity of Chronic Obstructive Pulmonary Disease (COPD), which includes chronic bronchitis and emphysema. Patients presenting with chronic cough, progressive exertional dyspnea, and a history of tobacco smoke or biomass fuel exposure undergo PFTs to detect persistent, non-reversible airflow limitation. The test assists the clinician by measuring the Forced Expiratory Volume in 1 second (FEV1) and the Forced Vital Capacity (FVC). A post-bronchodilator FEV1/FVC ratio of less than 0.70 confirms the presence of persistent airflow limitation, allowing for accurate staging and the formulation of an optimal therapeutic regimen.

Evaluation of Asthma and Airway Hyperresponsiveness

Asthma is characterized by chronic airway inflammation and variable, reversible airflow obstruction. A PFT is essential when patients present with episodic wheezing, chest tightness, and a dry cough, particularly when symptoms are triggered by allergens, exercise, or cold air. By performing a pre- and post-bronchodilator spirometry test, Dr. Essa Lab’s advanced diagnostic systems can measure the degree of airway reversibility. An increase in FEV1 of more than 12% and 200 mL after bronchodilator inhalation strongly supports a diagnosis of asthma, helping physicians differentiate it from other obstructive airway disorders.

Assessment of Interstitial Lung Disease (ILD)

Interstitial Lung Diseases (ILD) encompass a diverse group of disorders characterized by progressive inflammation and scarring of the lung parenchyma. Patients typically present with progressive shortness of breath and a dry, hacking cough. Physicians utilize PFTs to detect restrictive lung patterns and assess the impairment of gas exchange across the alveolar-capillary membrane. By measuring Total Lung Capacity (TLC) and the Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO), the test provides critical diagnostic evidence of lung stiffness, helping to monitor disease progression and response to immunosuppressive or antifibrotic therapies.

Pre-Operative Risk Stratification

Prior to undergoing major cardiothoracic, upper abdominal, or prolonged general surgeries, patients with a history of smoking, respiratory symptoms, or pre-existing lung disease require a comprehensive pre-operative PFT. This assessment helps the surgical and anesthesia teams evaluate the patient’s pulmonary reserve and estimate the risk of post-operative pulmonary complications, such as respiratory failure, atelectasis, or prolonged mechanical ventilation. The objective data provided by the PFT guides pre-operative optimization, intra-operative ventilation strategies, and post-operative respiratory care plans.

Monitoring Occupational and Environmental Lung Exposure

Individuals working in industries with high exposure to dust, silica, asbestos, coal, chemical fumes, or organic antigens are at significant risk for developing occupational lung diseases. Physicians recommend regular, serial Pulmonary Function Tests for these workers to monitor for early signs of lung injury before clinical symptoms manifest. By tracking annual declines in FEV1, FVC, and DLCO, healthcare providers can detect early restrictive or obstructive patterns, implement timely workplace interventions, and prevent irreversible, progressive parenchymal damage.

What Does a Pulmonary Function Test (PFT) Detect?

A comprehensive Pulmonary Function Test (PFT) at Dr. Essa Lab provides critical diagnostic insights by detecting a wide range of physiological abnormalities. These findings help clinicians pinpoint the exact nature of respiratory impairment. The test detects:

• Obstructive Lung Defects: Characterized by a disproportionate reduction in airflow relative to lung volume, typically indicated by a decreased FEV1/FVC ratio.
• Restrictive Lung Defects: Identified by a reduction in total lung capacity (TLC) with a preserved or elevated FEV1/FVC ratio.
• Asthma Reversibility: Indicated by a significant improvement in FEV1 (typically >12% and >200 mL) after administering a bronchodilator.
• Emphysema: Suggested by a reduction in diffusing capacity (DLCO) combined with increased residual volume (RV) due to alveolar destruction.
• Chronic Bronchitis: Marked by persistent airflow obstruction with normal or near-normal diffusing capacity.
• Pulmonary Fibrosis: Characterized by severe restrictive patterns, reduced lung volumes, and significantly impaired gas transfer (low DLCO).
• Respiratory Muscle Weakness: Indicated by reduced maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP).
• Air Trapping: Indicated by an elevated residual volume (RV) to total lung capacity (TLC) ratio.
• Lung Hyperinflation: Characterized by abnormally high TLC, often seen in advanced obstructive diseases.
• Scoliosis-Induced Restriction: Extrapulmonary restriction caused by thoracic cage deformities.
• Neuromuscular Dysfunctions: Such as ALS or Myasthenia Gravis, which manifest as progressive restrictive patterns.
• Pulmonary Vascular Disease: Suggested by an isolated reduction in DLCO with normal lung volumes.
• Sarcoidosis: Detected through a combination of restrictive patterns and impaired gas exchange.
• Asbestosis: Occupational lung damage presenting as restrictive impairment and reduced DLCO.
• Cystic Fibrosis: Showing severe mixed obstructive and restrictive patterns with significant air trapping.
• Vocal Cord Dysfunction: Identified via characteristic flattening of the inspiratory loop on the flow-volume curve.
• Tracheal Stenosis: Indicated by fixed upper airway obstruction patterns on the flow-volume loop.
• Obesity Hypoventilation Syndrome: Presenting as restrictive physiology due to chest wall loading.
• Drug-Induced Pulmonary Toxicity: Such as amiodarone or methotrexate toxicity, showing restrictive changes.
• Early Small Airway Disease: Indicated by abnormalities in terminal expiratory flows (FEF25-75%).

Turnaround Time and Report Access at Dr. Essa Lab

At Dr. Essa Lab, we understand that timely diagnostic results are crucial for effective clinical decision-making and patient peace of mind. The raw data from your Pulmonary Function Test is captured digitally by our advanced diagnostic software immediately upon completion of the procedure. This data is then meticulously reviewed, interpreted, and signed off by our highly qualified consultant pathologists and clinical specialists who specialize in respiratory diagnostics.

The finalized, comprehensive PFT report is typically available within 24 to 48 hours of the test completion. Dr. Essa Lab provides multiple convenient methods for patients to access their reports. Patients receive an automatic SMS notification containing a secure direct link to download their digital report in PDF format as soon as it is verified. Additionally, reports can be accessed online through the official Dr. Essa Lab web portal by entering the patient’s unique lab ID and password. For those who prefer physical copies, printed reports can be collected directly from the reception desk of the respective testing branch in Karachi or other regional centers.

Pulmonary Function Test (PFT) Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Forced Expiratory Volume in 1 Second (FEV1)	≥ 80% of predicted value based on age, sex, and height	< 80% of predicted value (indicates obstructive or restrictive lung disease)
Forced Vital Capacity (FVC)	≥ 80% of predicted value	< 80% of predicted value (suggests restrictive defect or severe air trapping)
FEV1/FVC Ratio	≥ 0.70 (or above the Lower Limit of Normal)	< 0.70 (diagnostic of obstructive airway disease like asthma or COPD)
Total Lung Capacity (TLC)	80% to 120% of predicted value	< 80% (confirms restrictive lung disease); > 120% (indicates hyperinflation)
Residual Volume (RV)	80% to 120% of predicted value	> 120% (indicates air trapping, common in emphysema and severe asthma)
Diffusing Capacity (DLCO)	≥ 80% of predicted value	< 80% (indicates alveolar-capillary membrane damage, emphysema, or ILD)
Forced Expiratory Flow (FEF25-75%)	60% to 150% of predicted value	< 60% (suggests early-stage small airway disease or mild obstruction)
Maximal Voluntary Ventilation (MVV)	80% to 120% of predicted value	< 80% (indicates respiratory muscle weakness, poor effort, or severe obstruction)

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Dr. Essa Lab for Pulmonary Function Test (PFT)?

• Experienced Healthcare Professionals: Our dedicated team of pulmonologists, technologists, and pathologists ensures highly accurate testing and interpretation.
• Patient-Focused Care: We prioritize patient comfort and safety throughout the entire testing process.
• Quality Diagnostic Services: Dr. Essa Lab is committed to maintaining the highest standards of diagnostic accuracy and clinical excellence.
• Professional Reporting: Detailed, easy-to-understand reports reviewed by qualified medical specialists.
• Modern Diagnostic Approach: Utilizing state-of-the-art spirometers and pulmonary diagnostic equipment.
• Comfortable Environment: Clean, hygienic, and welcoming clinical facilities designed for patient ease.
• Convenient Location: Easily accessible branches across Karachi and other major cities.
• Commitment to Accurate Diagnosis: Strict quality control protocols to ensure reliable and reproducible test results.